Neuron News and Research

RSS

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Repligen Corporation today reported results for the first quarter of fiscal year 2011, ended June 30, 2010. Total revenue for the first quarter was $7,010,000 compared to total revenue of $5,061,000 for the first quarter of fiscal year 2010, an increase of $1,949,000 or 39%. Bioprocessing product revenue for the first quarter was $4,269,000 compared to $2,473,000 for the first quarter of fiscal 2010, an increase of $1,796,000 or 73%.

5 Aug 2010

Genomic sequence of living marine sponge reveals some basic information about cancer: Scientists

This week's publication of the complete genomic sequence of a living marine sponge reveals genes dating back hundreds of millions of years -- a result far exceeding the expectations of the scientific world.

5 Aug 2010

Scientists study specific cell interactions for reasearch on human developmental disorders

Two University of Iowa biologists have published a paper on how cells make specific interactions during development -- in the hope of one day learning more about human developmental disorders -- in the Aug. 2 issue of the journal Proceedings of the National Academy of Sciences.

4 Aug 2010

Measuring GAPDH inhibiting antibodies can result in long-term treatment for MS

UCI immunologists have found that testing for increased levels of antibodies that inhibit energy production in neurons can detect axon and neuron degeneration in multiple sclerosis earlier than existing diagnostic tools.

31 Jul 2010

Tel Aviv University discovers molecular power behind memory

Neuroscientists have long wondered how individual connections between brain cells remain diverse and "fit" enough for storing new memories. Reported in the prestigious science journal Neuron, a new study led by Dr. Inna Slutsky of the Sackler School of Medicine at Tel Aviv University describes what makes some memories stick.

30 Jul 2010

Scientists identify new targets to develop treatment for HD

Scientists at the Buck Institute for Age Research have discovered that a particular family of enzymes are involved in the breakdown of proteins that modify the production of toxic fragments that lead to the pathology of Huntington's disease. These enzymes, matrix metalloproteinases, provide new targets for drug therapies for the disease - targets that have already been shown to respond to cancer drugs currently in clinical development.

29 Jul 2010

Genetic signals determine neurotransmitter use for communication

Cascades of genetic signals determine which neurotransmitter a brain cell will ultimately use to communicate with other cells. Now a pair of reports from biologists at the University of California, San Diego, have shown for the first time that electrical activity in these developing neurons can alter their chemical fate-and change an animal's behavior-by tweaking this genetic program.

29 Jul 2010

Inhibition of MMPs can offer therapeutic benefit in Huntington's disease: Study

A new study reveals that an enzyme linked with multiple disorders is also involved in the generation of toxic, neuron-killing protein fragments in Huntington's disease (HD). The research, published by Cell Press in the July 29 issue of Neuron, provides insight into Huntington's pathology and proposes new therapeutic strategies for this devastating incurable disease.

29 Jul 2010

Major breakthrough in Alzheimer's disease research

Researchers from the University of Sydney's Alzheimer's and Parkinson's Disease Laboratory have achieved a major breakthrough by finding the causes of Alzheimer's disease at a cellular level and thereby identifying a potential therapy as a result.

23 Jul 2010

Protein parkin essential for hypothalamic neurons recovery in Parkinson's disease patients

A Michigan State University researcher is working to uncover how a protein known as parkin may help nerve cells fight off damage from Parkinson's disease, a strategy that could lead to new therapies for the degenerative ailment.

23 Jul 2010

Brain neuron activity can signal initiation, termination of behavioural sequences: Study

Rui Costa, Principal Investigator of the Champalimaud Neuroscience Programme at the Instituto Gulbenkian de Ciência, and Xin Jin, of the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, describe in the latest issue of the journal Nature, that the activity of certain neurons in the brain can signal the initiation and termination of behavioural sequences we learn anew. Furthermore, they found that this brain activity is essential for learning and executing novel action sequences, many times compromised in patients suffering from disorders such as Parkinson's or Huntington's.

22 Jul 2010

Mental exercises may help reverse age-related cognitive decline

Specialized brain training targeted at the regions of a rat's brain that process sound reversed many aspects of normal, age-related cognitive decline and improved the health of the brain cells, according to a new study from researchers at University of California, San Francisco.

21 Jul 2010

Winston Laboratories receives NOC for CIVANEX

Winston Laboratories, Inc., a wholly-owned subsidiary of Winston Pharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing novel pain management therapies, announced that it has received Notice of Compliance from the Therapeutics Drug Directorate, Health Canada for its New Drug Submission for CIVANEX (zucapsaicin cream 0.075%) for the treatment of the signs and symptoms of osteoarthritis.

20 Jul 2010

Penn researchers reverse cognitive decline in fruit flies with Alzheimer's gene mutation

Investigators have found that fruit fly (Drosophila melanogaster) males -- in which the activity of an Alzheimer's disease protein is reduced by 50 percent -- show impairments in learning and memory as they age. What's more, the researchers were able to prevent the age-related deficits by treating the flies with drugs such as lithium, or by genetic manipulations that reduced nerve-cell signaling.

16 Jul 2010

Columbia scientists discover new way to alleviate chronic pain

Columbia scientists working to combat injury-related depression, substance abuse and suicide due to unremitting, persistent pain may have discovered a new way of treating that pain: a powerful analgesic dubbed N60 that leads to neither tolerance nor addiction.

16 Jul 2010

Noscira presents results of Nypta Phase IIa clinical trial for AD at ICAD 2010

Noscira, the Grupo Zeltia (ZEL.MC) subsidiary specialized in researching and developing drugs for treating neurodegenerative diseases, presented the results of a Phase IIa clinical trial of Nypta(R) (Tideglusib) on Alzheimer's disease (AD) at the International Conference on Alzheimer's Disease (ICAD), held in Honolulu (Hawaii) from July 10-15, 2010.

16 Jul 2010

Intrinsically photosensitive Retinal Ganglion Cells help blind mice 'see'

It would make the perfect question for the popular television show "Are You Smarter than a 5th Grader:" What parts of the eye allow us to see?

15 Jul 2010

New research studies presented at Alzheimer's Association International Conference

The primary therapeutic target in Alzheimer's disease has been the beta amyloid peptide, which clusters outside cells in the brain to form sticky clumps known as plaques. Recently, more attention has been given to the tau protein, which aggregates inside the brain cells of people with Alzheimer's, forming neurofibrillary tangles. Precisely how these proteins interact in causing the disease is unclear.

14 Jul 2010

CSHL scientists reverse symptoms of Type III SMA using ASOs

The devastating, currently incurable motor-neuron disease spinal muscular atrophy might soon be treated with tiny, chemically modified pieces of RNA called antisense oligonucleotides.

13 Jul 2010

Japanese scientists identify long-elusive enzyme necessary for proper regulation of cilia

It's safe to say that cilia, the hairlike appendages jutting out from the smooth surfaces of most mammalian cells, have long been misunderstood - underestimated, even.

8 Jul 2010

Neuron News and Research

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Genomic sequence of living marine sponge reveals some basic information about cancer: Scientists

Scientists study specific cell interactions for reasearch on human developmental disorders

Measuring GAPDH inhibiting antibodies can result in long-term treatment for MS

Tel Aviv University discovers molecular power behind memory

Scientists identify new targets to develop treatment for HD

Genetic signals determine neurotransmitter use for communication

Inhibition of MMPs can offer therapeutic benefit in Huntington's disease: Study

Major breakthrough in Alzheimer's disease research

Protein parkin essential for hypothalamic neurons recovery in Parkinson's disease patients

Brain neuron activity can signal initiation, termination of behavioural sequences: Study

Mental exercises may help reverse age-related cognitive decline

Winston Laboratories receives NOC for CIVANEX

Penn researchers reverse cognitive decline in fruit flies with Alzheimer's gene mutation

Columbia scientists discover new way to alleviate chronic pain

Noscira presents results of Nypta Phase IIa clinical trial for AD at ICAD 2010

Intrinsically photosensitive Retinal Ganglion Cells help blind mice 'see'

New research studies presented at Alzheimer's Association International Conference

CSHL scientists reverse symptoms of Type III SMA using ASOs

Japanese scientists identify long-elusive enzyme necessary for proper regulation of cilia

Neuroscience - Second Edition eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News